Pfizer Norvasc Patent Term Extension Keeps AmVaz Off The Market Until 2007
Executive Summary
Pfizer's Norvasc (amlodipine besylate) will not face competition from Dr. Reddy's calcium channel blocker AmVaz until 2007 under a federal appeals court ruling
You may also be interested in...
Crestor Patent Battle Could Have Ripple Effect: Is A Salt Equivalent To Base Compound?
Watson filed a 505(b)(2) NDA for a zinc salt of AstraZeneca’s Crestor, which AstraZeneca claims infringes its patent; if Watson prevails more generic manufacturers may pursue this pathway around a patent.
Pfizer, Novartis Learning The VALUE Of Comparative Research
A Novartis-sponsored study comparing Diovan to Pfizer's Norvasc highlights the risk firms take in conducting comparative research
Pfizer, Novartis Learning The VALUE Of Comparative Research
A Novartis-sponsored study comparing Diovan to Pfizer's Norvasc highlights the risk firms take in conducting comparative research